IntelliPharmaCeutics Intl Stock Price, News & Analysis (NASDAQ:IPCI)

$0.70 +0.02 (+2.94 %)
(As of 02/22/2018 08:18 AM ET)
Previous Close$0.68
Today's Range$0.68 - $0.70
52-Week Range$0.66 - $2.92
Volume93,900 shs
Average Volume486,063 shs
Market Capitalization$23.67 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06

About IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl logoIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Receive IPCI News and Ratings via Email

Sign-up to receive the latest news and ratings for IPCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IPCI
CUSIPN/A
Phone416-798-3001

Debt

Debt-to-Equity RatioN/A
Current Ratio0.52%
Quick Ratio0.48%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.51 million
Price / Sales4.41
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book17.50

Profitability

Trailing EPS($0.29)
Net Income$-8,860,000.00
Net Margins-160.89%
Return on Equity-3,019.43%
Return on Assets-118.78%

Miscellaneous

Employees54
Outstanding Shares34,710,000

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Frequently Asked Questions

What is IntelliPharmaCeutics Intl's stock symbol?

IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI."

How were IntelliPharmaCeutics Intl's earnings last quarter?

IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) released its quarterly earnings data on Thursday, October, 13th. The company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The firm earned $0.56 million during the quarter, compared to the consensus estimate of $0.50 million. IntelliPharmaCeutics Intl had a negative net margin of 160.89% and a negative return on equity of 3,019.43%. View IntelliPharmaCeutics Intl's Earnings History.

When will IntelliPharmaCeutics Intl make its next earnings announcement?

IntelliPharmaCeutics Intl is scheduled to release their next quarterly earnings announcement on Tuesday, April, 10th 2018. View Earnings Estimates for IntelliPharmaCeutics Intl.

Where is IntelliPharmaCeutics Intl's stock going? Where will IntelliPharmaCeutics Intl's stock price be in 2018?

4 brokerages have issued 12-month target prices for IntelliPharmaCeutics Intl's stock. Their predictions range from $2.00 to $3.10. On average, they anticipate IntelliPharmaCeutics Intl's stock price to reach $2.53 in the next year. View Analyst Ratings for IntelliPharmaCeutics Intl.

What are Wall Street analysts saying about IntelliPharmaCeutics Intl stock?

Here are some recent quotes from research analysts about IntelliPharmaCeutics Intl stock:

  • 1. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (2/20/2018)
  • 2. Maxim Group analysts commented, "Reported this morning, 4Q17 revenues were $1.08M, down from $1.19M in 3Q17. The company ended the period with $1.9M in cash, but as of February 2018, has just $0.6M in cash. Management expects this to last until June even when considering quarterly profit share payments from Par Pharmaceuticals (private) and Mallinckrodt (MNK – NR). As such, we expect the company will need to raise capital which will likely be dilutive, and along with sequentially lower revenue in 4Q, we downgrade the shares to Hold, from Buy, and remove the price target." (2/16/2018)

Who are some of IntelliPharmaCeutics Intl's key competitors?

Who are IntelliPharmaCeutics Intl's key executives?

IntelliPharmaCeutics Intl's management team includes the folowing people:

  • Isa Odidi Ph.D., Chairman of the Board, Chief Executive Officer
  • Amina Odidi Ph.D., President, Chief Operating Officer, Director
  • Andrew Patient, Chief Financial Officer
  • John N. Allport, Vice President - Legal Affairs and Licensing, Secretary, Director
  • Patrick N. Yat Ph.D., Vice President - Pharmaceutical Analysis and Chemistry
  • Kenneth Keirstead, Independent Director
  • Bahadur Madhani, Independent Director
  • Eldon R. Smith M.D., Independent Director (Age 75)

Who owns IntelliPharmaCeutics Intl stock?

IntelliPharmaCeutics Intl's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (6.23%) and Sabby Management LLC (3.49%). View Institutional Ownership Trends for IntelliPharmaCeutics Intl.

Who bought IntelliPharmaCeutics Intl stock? Who is buying IntelliPharmaCeutics Intl stock?

IntelliPharmaCeutics Intl's stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC and Sabby Management LLC. View Insider Buying and Selling for IntelliPharmaCeutics Intl.

How do I buy IntelliPharmaCeutics Intl stock?

Shares of IntelliPharmaCeutics Intl can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IntelliPharmaCeutics Intl's stock price today?

One share of IntelliPharmaCeutics Intl stock can currently be purchased for approximately $0.70.

How big of a company is IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl has a market capitalization of $23.67 million and generates $5.51 million in revenue each year. The company earns $-8,860,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. IntelliPharmaCeutics Intl employs 54 workers across the globe.

How can I contact IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl's mailing address is 30 WORCESTER ROAD, TORONTO A6, M9W 5X2. The company can be reached via phone at 416-798-3001 or via email at [email protected]


MarketBeat Community Rating for IntelliPharmaCeutics Intl (IPCI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about IntelliPharmaCeutics Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyHoldBuy
Consensus Rating Score: 2.252.502.332.67
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.53$2.40$2.37$4.00
Price Target Upside: 227.92% upside200.00% upside134.32% upside60.64% upside

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Consensus Price Target History

Price Target History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018Maxim GroupDowngradeBuy -> HoldMediumView Rating Details
2/12/2018HC WainwrightSet Price TargetBuy$3.00HighView Rating Details
9/26/2017MackieUpgradeHold$1.00 -> $3.10MediumView Rating Details
4/18/2017AegisReiterated RatingHold$2.00LowView Rating Details
10/17/2016Brean CapitalSet Price TargetBuy$8.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Earnings History and Estimates Chart

Earnings by Quarter for IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl (NASDAQ IPCI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/10/2018        
10/10/2017Q3 2017($0.04)($0.08)$2.45 million$1.19 millionViewN/AView Earnings Details
7/11/2017Q2 2017($0.05)($0.06)$1.86 million$2.00 millionViewN/AView Earnings Details
4/11/2017Q1 2017($0.08)($0.07)$2.30 million$1.24 millionViewN/AView Earnings Details
2/10/2017Q4 2016($0.06)($0.14)$0.60 million$0.57 millionViewN/AView Earnings Details
10/13/2016Q316($0.07)($0.07)$0.50 million$0.56 millionViewN/AView Earnings Details
7/13/2016Q216($0.09)($0.08)$0.80 million$0.56 millionViewN/AView Earnings Details
4/14/2016Q1($0.07)($0.09)$0.70 million$0.57 millionViewN/AView Earnings Details
2/26/2016Q4 2015($0.06)($0.13)$1.20 million$0.85 millionViewN/AView Earnings Details
10/9/2015Q315($0.05)($0.08)$1.30 million$0.84 millionViewN/AView Earnings Details
7/13/2015Q215($0.05)($0.06)$1.20 million$1.27 millionViewN/AView Earnings Details
4/14/2015Q1 2015($0.08)($0.04)$1.20 million$1.14 millionViewN/AView Earnings Details
2/23/2015Q4 2014($0.07)($0.06)$1.40 million$1.54 millionViewN/AView Earnings Details
10/15/2014Q3($0.05)($0.07)$2.40 million$1.07 millionViewN/AView Earnings Details
7/7/2014Q2 2014($0.14)$2.00 million$1.48 millionViewN/AView Earnings Details
4/14/2014Q114$0.11$0.09$4.49 million$4.70 millionViewN/AView Earnings Details
2/18/2014($0.08)($0.31)$4.25 million$1.53 millionViewN/AView Earnings Details
10/1/2013Q3 2013($0.10)($0.10)ViewN/AView Earnings Details
7/2/2013Q2 2013($0.15)($0.10)ViewN/AView Earnings Details
4/3/2013Q113($0.12)($0.07)ViewN/AView Earnings Details
1/31/2013Q4 2012($0.12)($0.14)ViewN/AView Earnings Details
10/2/2012Q3 2012($0.12)($0.11)ViewN/AView Earnings Details
7/3/2012Q2 2012($0.15)($0.13)ViewN/AView Earnings Details
5/10/2012Q4 2011$0.03ViewN/AView Earnings Details
4/12/2012Q1 2012($0.13)($0.12)ViewN/AView Earnings Details
10/7/2011Q3 2011($0.14)($0.09)ViewN/AView Earnings Details
7/5/2011Q2 2011($0.13)($0.16)ViewN/AView Earnings Details
4/14/2011Q1 2011($0.15)($0.12)ViewN/AView Earnings Details
10/15/2010Q3 2010($0.20)ViewN/AView Earnings Details
7/14/2010Q2 2010($0.04)ViewN/AView Earnings Details
4/13/2010Q1 2010($0.13)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.13)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.01)ViewN/AView Earnings Details
7/14/2009Q2 2009($0.27)ViewN/AView Earnings Details
4/13/2009Q1 2009($0.59)ViewN/AView Earnings Details
2/27/2009Q4 2008($0.39)ViewN/AView Earnings Details
10/15/2008Q3 2008($1.23)ViewN/AView Earnings Details
7/9/2008Q2 2008($5.00)ViewN/AView Earnings Details
4/3/2008Q1 2008($3.64)ViewN/AView Earnings Details
1/16/2008Q4 2007($3.94)($4.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.13 EPS
Next Year EPS Consensus Estimate: $0.05 EPS

Dividends

Dividend History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for IntelliPharmaCeutics Intl (NASDAQ IPCI)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

IntelliPharmaCeutics Intl (NASDAQ IPCI) News Headlines

Source:
DateHeadline
Maxim Group Lowers IntelliPharmaCeutics Intl (IPCI) to HoldMaxim Group Lowers IntelliPharmaCeutics Intl (IPCI) to Hold
www.americanbankingnews.com - February 16 at 3:34 PM
Intellipharmaceutics Announces Fiscal Year 2017 ResultsIntellipharmaceutics Announces Fiscal Year 2017 Results
finance.yahoo.com - February 16 at 9:29 AM
 Brokerages Anticipate IntelliPharmaCeutics Intl Inc (IPCI) to Post -$0.07 Earnings Per Share Brokerages Anticipate IntelliPharmaCeutics Intl Inc (IPCI) to Post -$0.07 Earnings Per Share
www.americanbankingnews.com - February 14 at 11:16 PM
Intellipharmaceutics Sets Earnings Release Date for Year End 2017 ResultsIntellipharmaceutics Sets Earnings Release Date for Year End 2017 Results
finance.yahoo.com - February 14 at 6:02 AM
IntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of "Hold" from AnalystsIntelliPharmaCeutics Intl Inc (IPCI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 13 at 9:22 AM
IntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target at HC WainwrightIntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 12 at 7:52 PM
Maxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price TargetMaxim Group Analysts Give IntelliPharmaCeutics Intl (IPCI) a $2.00 Price Target
www.americanbankingnews.com - February 9 at 9:30 PM
Intellipharmaceutics (IPCI) Announced Completed Meetings with ... - StreetInsider.comIntellipharmaceutics (IPCI) Announced Completed Meetings with ... - StreetInsider.com
www.streetinsider.com - February 9 at 3:27 PM
Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development ProgramIntellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program
finance.yahoo.com - February 9 at 3:27 PM
Reviewing IntelliPharmaCeutics Intl (IPCI) and Marinus Pharmaceuticals (MRNS)Reviewing IntelliPharmaCeutics Intl (IPCI) and Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - February 3 at 5:14 PM
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $1.32 MillionIntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $1.32 Million
www.americanbankingnews.com - January 30 at 1:52 AM
 Analysts Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share Analysts Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - January 28 at 11:10 PM
Intellipharmaceutics Provides Operational Update - GlobeNewswire (press release)Intellipharmaceutics Provides Operational Update - GlobeNewswire (press release)
globenewswire.com - January 26 at 5:53 AM
Intellipharmaceutics (IPCI) Announces Operational Update - StreetInsider.comIntellipharmaceutics (IPCI) Announces Operational Update - StreetInsider.com
www.streetinsider.com - January 24 at 3:23 PM
IntelliPharmaCeutics Intl (IPCI) Coverage Initiated at HC WainwrightIntelliPharmaCeutics Intl (IPCI) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - January 20 at 7:38 PM
IntelliPharmaCeutics Intl Inc (IPCI) Receives Average Recommendation of "Hold" from BrokeragesIntelliPharmaCeutics Intl Inc (IPCI) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 19 at 10:32 AM
$1.75 Million in Sales Expected for IntelliPharmaCeutics Intl Inc (IPCI) This Quarter$1.75 Million in Sales Expected for IntelliPharmaCeutics Intl Inc (IPCI) This Quarter
www.americanbankingnews.com - January 14 at 2:04 PM
AzurRx BioPharma (AZRX) versus IntelliPharmaCeutics Intl (IPCI) Head to Head ReviewAzurRx BioPharma (AZRX) versus IntelliPharmaCeutics Intl (IPCI) Head to Head Review
www.americanbankingnews.com - January 13 at 5:54 AM
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Earnings of -$0.08 Per ShareIntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - January 12 at 1:18 AM
Teligent (TLGT) & IntelliPharmaCeutics Intl (IPCI) Head to Head ContrastTeligent (TLGT) & IntelliPharmaCeutics Intl (IPCI) Head to Head Contrast
www.americanbankingnews.com - January 10 at 5:10 AM
 Brokerages Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share Brokerages Expect IntelliPharmaCeutics Intl Inc (IPCI) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - December 26 at 1:37 PM
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Post Earnings of -$0.08 Per ShareIntelliPharmaCeutics Intl Inc (IPCI) Expected to Post Earnings of -$0.08 Per Share
www.americanbankingnews.com - December 26 at 1:34 PM
IntelliPharmaCeutics Intl (IPCI) Downgraded by Zacks Investment ResearchIntelliPharmaCeutics Intl (IPCI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 21 at 12:14 AM
IntelliPharmaCeutics Intl (IPCI) Rating Increased to Hold at Zacks Investment ResearchIntelliPharmaCeutics Intl (IPCI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - December 17 at 3:08 PM
IntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $3.25 MillionIntelliPharmaCeutics Intl Inc (IPCI) Expected to Announce Quarterly Sales of $3.25 Million
www.americanbankingnews.com - December 10 at 2:54 AM
$3.25 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter$3.25 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter
www.americanbankingnews.com - November 22 at 2:22 AM
-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter
www.americanbankingnews.com - November 20 at 11:12 PM
 Analysts Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Quarterly Sales of $3.25 Million Analysts Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Quarterly Sales of $3.25 Million
www.americanbankingnews.com - November 19 at 8:26 PM
Head-To-Head Analysis: Intellipharmaceutics International (IPCI) and Its RivalsHead-To-Head Analysis: Intellipharmaceutics International (IPCI) and Its Rivals
www.americanbankingnews.com - November 3 at 7:53 AM
 Analysts Anticipate Intellipharmaceutics International Inc. (IPCI) Will Post Quarterly Sales of $3.25 Million Analysts Anticipate Intellipharmaceutics International Inc. (IPCI) Will Post Quarterly Sales of $3.25 Million
www.americanbankingnews.com - October 29 at 4:02 AM
Reviewing Intellipharmaceutics International (IPCI) and The CompetitionReviewing Intellipharmaceutics International (IPCI) and The Competition
www.americanbankingnews.com - October 27 at 11:48 AM
Intellipharmaceutics International Inc. (IPCI) Short Interest Down 57.7% in SeptemberIntellipharmaceutics International Inc. (IPCI) Short Interest Down 57.7% in September
www.americanbankingnews.com - October 14 at 1:40 AM
Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017Intellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q3, 2017 By the Numbers : October 13, 2017
finance.yahoo.com - October 13 at 7:48 PM
New Strong Sell Stocks for October 11th - NasdaqNew Strong Sell Stocks for October 11th - Nasdaq
www.nasdaq.com - October 11 at 9:46 PM
Intellipharmaceutics Announces US$4 Million Registered Direct Offering - GlobeNewswire (press release)Intellipharmaceutics Announces US$4 Million Registered Direct Offering - GlobeNewswire (press release)
globenewswire.com - October 11 at 9:46 PM
Your Daily Pharma Scoop: Alexions Catalysts, Amgens Prolia, Ultragenyx BorosumabYour Daily Pharma Scoop: Alexion's Catalysts, Amgen's Prolia, Ultragenyx Borosumab
seekingalpha.com - October 11 at 4:42 PM
Intellipharmaceutics Announces US$4 Million Registered Direct OfferingIntellipharmaceutics Announces US$4 Million Registered Direct Offering
finance.yahoo.com - October 11 at 4:42 PM
New Strong Sell Stocks for October 11thNew Strong Sell Stocks for October 11th
finance.yahoo.com - October 11 at 4:42 PM
$2.45 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter$2.45 Million in Sales Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter
www.americanbankingnews.com - October 10 at 7:18 AM
 Brokerages Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Earnings of -$0.04 Per Share Brokerages Expect Intellipharmaceutics International Inc. (IPCI) Will Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - October 8 at 4:22 PM
Analyzing Intellipharmaceutics International (IPCI) and Its CompetitorsAnalyzing Intellipharmaceutics International (IPCI) and Its Competitors
www.americanbankingnews.com - October 5 at 9:46 AM
DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses Over $100,000 to Contact the FirmDEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses Over $100,000 to Contact the Firm
finance.yahoo.com - October 2 at 1:05 PM
Intellipharmaceutics International Inc. (IPCI) Given Consensus Rating of "Hold" by BrokeragesIntellipharmaceutics International Inc. (IPCI) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 26 at 12:52 PM
Intellipharmaceutics International Inc. (IPCI) Raised to "Hold" at MackieIntellipharmaceutics International Inc. (IPCI) Raised to "Hold" at Mackie
www.americanbankingnews.com - September 26 at 11:50 AM
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against IntelliPharmaCeutics International Inc. (IPCI) and Lead Plaintiff Deadline - September 29, 2017
finance.yahoo.com - September 25 at 4:41 PM
DEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the FirmDEADLINE FRIDAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 25 at 4:41 PM
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA - GlobeNewswire (press release)Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA - GlobeNewswire (press release)
globenewswire.com - September 25 at 9:32 AM
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDAIntellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA
finance.yahoo.com - September 25 at 9:32 AM
FDA declines to approve Intellipharmas opioid painkillerFDA declines to approve Intellipharma's opioid painkiller
finance.yahoo.com - September 25 at 9:32 AM
Intellipharmaceutics International Inc. (IPCI) Expected to Announce Quarterly Sales of $4.55 MillionIntellipharmaceutics International Inc. (IPCI) Expected to Announce Quarterly Sales of $4.55 Million
www.americanbankingnews.com - September 21 at 1:48 AM

SEC Filings

IntelliPharmaCeutics Intl (NASDAQ:IPCI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

IntelliPharmaCeutics Intl (NASDAQ:IPCI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

IntelliPharmaCeutics Intl (NASDAQ IPCI) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.